A fully Open Access journal publishing antibody research on topics including targets relevant to cancer and immune-mediated disorders as well as antibody therapeutics, mAbs (2023 Impact Factor: 5.6) has a strong scientific and medical focus, while proudly serving a broad readership, including specialists in technology transfer, legal issues, investment, planning and the regulation of therapeutics.